Empowering early-stage life sciences companies with access to global capital, stronger pitch visibility, and expert insight, LSX World Congress Europe has become one of the most important meeting points for the global life sciences investment community.
This year, with thousands of curated 1:1 meetings taking place across the week — and co-located with BIO-Europe Spring — the event further cemented its position as a leading forum for life sciences companies focused on fundraising, capital markets access and strategic growth.
Against this backdrop, DFIN was pleased to support LSX World Congress Europe once again, continuing our long-standing involvement with the LSX community and engaging with companies preparing for their next phase of innovation and growth.
IPO Readiness Is No Longer a Late-Stage Exercise
A recurring theme across LSX Europe 2026 was the shift in how life sciences companies approach IPO preparation. In today’s dynamic market, readiness must begin well before any filing decision is made — often while companies are still privately funded and evaluating multiple capital pathways.
As part of LSX Europe, DFIN participated in the LSX US IPO Bootcamp webinar on 3 March, where panelists noted that even as markets trade through geopolitical uncertainty, successful U.S. IPOs are increasingly driven by early preparation, strong governance and disciplined execution. For European life sciences and biotech issuers in particular, that means allowing additional lead time for financial reporting, regulatory and governance readiness, and board education. The session also explored practical steps companies can take when considering a U.S. listing — including preparing financial reporting and disclosures to meet public-market expectations, coordinating finance, legal and advisory teams across jurisdictions, and building scalable, audit-ready processes that support life as a public company.
Technology is also playing a growing role across the IPO lifecycle, helping working groups reduce friction, improve accuracy and maintain control. As Ross Johnson, Managing Director, Global Capital Markets at DFIN, noted during the discussion:
“Technology now sits at the centre of IPO preparation and execution. From supporting confidential preparation and drafting through to managing disclosure obligations as a public company, platforms like DFIN ActiveDisclosure give working groups greater control, automation and accuracy in a secure, role-based environment. As AI adoption accelerates, we expect continued progress in removing friction and streamlining the IPO process.”
Engaging the Market in Lisbon: Capital Markets & Investment Strategies
These discussions continued on the ground in Lisbon from 24 to 26 March, as LSX World Congress Europe formed part of Spring Innovation Week alongside BIO-Europe Spring. With pre-day CEO forums, a three-track agenda spanning biotech, medtech and pharmatech, and a partnering programme built around high-density 1:1 meetings, the event brought together early- to growth-stage life sciences companies with an international mix of venture capital, growth investors, corporate venture teams, pharma business development leaders and specialist advisers.
In 2026, LSX Europe’s expanded scale — including hundreds of speakers and thousands of pre-arranged partner meetings — reinforced its position as one of Europe’s largest convenings for life sciences fundraising, capital markets access and strategic collaboration.
The Capital Markets & Investment Strategies programme focused on how companies can fund growth in a more disciplined market — from navigating venture and crossover dynamics to understanding IPO readiness, alternative routes to liquidity and cross-border execution. For management teams, the value was not only the content, but also the ability to pressure-test strategy in real time through meetings with investors and advisers who are actively deploying capital and supporting innovation.
One session that captured this focus was the panel Unlocking Opportunities in Public Markets: Strategies for Biotech Success, which explored optionality — how life sciences companies can stay prepared for private funding rounds, strategic transactions, or public listings as market conditions evolve.
“Exploring all options is increasingly critical. For resilient companies, it’s about approaching optionality in the right way — having the right management team and working with key advisers to navigate new challenges and assess the most appropriate instruments for accessing different markets.” Ross Johnson, Managing Director, Global Capital Markets, EMEA at DFIN, said during the panel.
For many biotech companies, “optionality” means doing the upfront work for several outcomes at once — staying credible with private investors for the next round, being ready to engage strategic partners, and keeping an IPO pathway viable when the window opens. That parallel preparation requires earlier rigour around governance, reporting discipline, and how critical documents are organised and controlled, so management teams can respond quickly to diligence requests without derailing day-to-day execution.
DFIN: Supporting Life Sciences Companies From Fundraising to IPO and Beyond
One theme came through clearly at LSX Europe: the groundwork for a future transaction or IPO often starts earlier than expected — especially when it comes to how sensitive information is organised and shared.
That’s where a virtual data room can help. Beyond fundraising or M&A, it gives teams a simple way to keep key clinical, regulatory and financial documents in one controlled, audit-ready platform, streamlining due diligence and IPO preparation in later stages. In practice, life sciences firms use DFIN’s Venue® Virtual Data Room to:
- Collaborate securely with investors, banks and legal counsel
- Share sensitive IP and deal documents (for example, licensing agreements) in a controlled environment aligned with GDPR and HIPAA requirements
- Apply granular permissions and maintain audit trails to support governance
- Use a structure that can scale from private fundraising through IPO preparation
As companies move toward a U.S. listing, the disclosure workload shifts — from drafting and reviewing IPO registration documents to meeting ongoing SEC reporting obligations as a public company (including annual reports, material disclosures and beneficial ownership filings). DFIN ActiveDisclosure supports this workflow digitally and cost‑effectively, providing secure data management, controlled versioning, and consistent audit trails, while minimising coordination risk and time to execution.
To discuss IPO readiness, fundraising requirements, or public-company reporting workflows, contact us for a consultation today.
